Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM2B | Q8NHM5 | 4/20 | 0.69 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.67 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.64 |
| ▸ | LMNA | P02545 | 2/20 | 0.57 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.53 |
| ▸ | MGLL | Q99685 | 1/20 | 0.53 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3966828 | 1.00 | KDM2B (0.69) | KDM2BL3MBTL1ALDH1A1LMNANPSR1 | |
| SCHEMBL21926483 | 0.90 | ALDH1A1 (0.72) | KDM2BL3MBTL1ALDH1A1MGLLKDM4E | |
| SCHEMBL21926486 | 0.87 | ALDH1A1 (0.76) | KDM2BL3MBTL1ALDH1A1MGLLKDM4E | |
| SCHEMBL21926514 | 0.86 | ALDH1A1 (0.70) | KDM2BL3MBTL1ALDH1A1MGLL | |
| SCHEMBL3723522 | 0.84 | ALDH1A1 (0.61) | KDM2BL3MBTL1ALDH1A1LMNA | |
| SCHEMBL3963250 | 0.84 | HPGD (0.56) | KDM2BL3MBTL1ALDH1A1MGLL | |
| SCHEMBL4082779 | 0.84 | ALDH1A1 (0.61) | KDM2BL3MBTL1ALDH1A1MGLLKDM4E | |
| Hydrochloric Acid SCHEMBL6998897 | 0.83 | ALDH1A1 (0.60) | KDM2BL3MBTL1ALDH1A1LMNA | |
| SCHEMBL13038072 | 0.83 | KDM2B (0.70) | KDM2BL3MBTL1ALDH1A1LMNANPSR1 | |
| SCHEMBL12023096 | 0.83 | KDM2B (0.72) | KDM2BL3MBTL1ALDH1A1LMNANPSR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-101072561-B | Diaminoalkane aspartic protease inhibitors | VITAE PHARMACEUTICALS INC | 2011-05-11 | — | — | CN | disclosed |
| US-20100010228-A1 | PROCESS FOR THE ASYMMETRIC REDUCTION OF 3-BENZOYLPIPERIDINES | VITAE PHARMACEUTICALS, INC. (US) | 2010-01-14 | — | — | US | disclosed |
| CN-101072561-A | Diaminoalkane aspartic protease inhibitors | VITAE PHARMACEUTICALS INC (US) | 2007-11-14 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100010228-A1 | PROCESS FOR THE ASYMMETRIC REDUCTION OF 3-BENZOYLPIPERIDINES | QDPR, ADH5, GABARAP | KDM2B 389/4885L3MBTL1 4343/4885ALDH1A1 151/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.